icon-    folder.gif   Conference Reports for NATAP  
  18th CROI
Conference on Retroviruses
and Opportunistic Infections
Boston, MA
February 27 - March 2, 2011
Back grey_arrow_rt.gif
The Effect of Low-dose Ritonavir on the Pharmacokinetics of the Investigational HCV Protease Inhibitor Telaprevir in Healthy Volunteers
  Reported by Jules Levin
CROI 2011 March 2 Boston
V Garg1, X Luo1, L McNair1*, R van Heeswijk2, and RS Kauffman1 1Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA ,2Tibotec BVBA, Beerse, Belgium



Telaprevir (TVR), an inhibitor of the hepatitis C virus (HCV) NS3/4A protease,1,2 is being developed as a treatment for hepatitis C infection in combination with pegylated interferon and ribavirin. In vitro studies suggested that TVR is both a substrate and an inhibitor of CYP3A. In addition, in vivo studies in rats demonstrated an increased plasma exposure of TVR when co-administered with ritonavir (RTV).3 The objective of this study was to evaluate the effect of low-dose RTV on the pharmacokinetics (PK) of TVR in human volunteers.